(Q36619428)

15 August 2017

1 reference

title

State-of-the-art management of metastatic disease at initial presentation or recurrence (English)

1 reference

15 August 2017

Fabio Calabrò

1

1 reference

PubMed ID

17031652

15 August 2017

Cora N Sternberg

series ordinal

2

1 reference

PubMed ID

17031652

15 August 2017

language of work or name

1 reference

1 November 2006

1 reference

15 August 2017

World Journal of Urology

1 reference

15 August 2017

24

1 reference

15 August 2017

543-556

1 reference

15 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00345-006-0115-x

15 August 2017

0 references

cites work

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-006-0115-X

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-006-0115-X

Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-006-0115-X

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

21 January 2018

1 reference

12 December 2020

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

1 reference

12 December 2020

Pemetrexed in bladder, head and neck, and cervical cancers

1 reference

12 December 2020

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

12 December 2020

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

12 December 2020

Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

1 reference

12 December 2020

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

12 December 2020

Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract

1 reference

12 December 2020

Cancer statistics, 2005

1 reference

12 December 2020

Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer

1 reference

12 December 2020

Proteasome: an emerging target for cancer therapy

1 reference

12 December 2020

Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study

1 reference

12 December 2020

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

12 December 2020

Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

1 reference

12 December 2020

Targeting HER2 in other tumor types

1 reference

12 December 2020

Phase II study of paclitaxel and cisplatin for advanced urothelial cancer

1 reference

12 December 2020

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

12 December 2020

Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report

1 reference

12 December 2020

Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

12 December 2020

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors

1 reference

12 December 2020

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

1 reference

12 December 2020

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

12 December 2020

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

12 December 2020

Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer

1 reference

12 December 2020

A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer

1 reference

12 December 2020

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

12 December 2020

Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer

1 reference

12 December 2020

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

12 December 2020

Pemetrexed disodium, a novel antifolate with multiple targets

1 reference

12 December 2020

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

1 reference

12 December 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group

1 reference

12 December 2020

Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors

1 reference

12 December 2020

Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

1 reference

12 December 2020

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

12 December 2020

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

12 December 2020

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

12 December 2020

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

1 reference

12 December 2020

Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.

1 reference

12 December 2020

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

12 December 2020

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

12 December 2020

Gemcitabine in bladder cancer

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

1 reference

12 December 2020

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

12 December 2020

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules

1 reference

12 December 2020

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel

1 reference

12 December 2020

Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial

1 reference

12 December 2020

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

12 December 2020

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

1 reference

12 December 2020

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

12 December 2020

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

1 reference

12 December 2020

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

1 reference

12 December 2020

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

12 December 2020

New drugs and new approaches in metastatic bladder cancer

1 reference

12 December 2020

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

12 December 2020

Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer

1 reference

12 December 2020

Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder

1 reference

12 December 2020

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

12 December 2020

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

12 December 2020

p53 and treatment of bladder cancer

1 reference

12 December 2020

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

12 December 2020

Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

1 reference

12 December 2020

Epothilones in the treatment of cancer

1 reference

12 December 2020

10.1007/S00345-006-0115-X

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17031652